Detalles de la búsqueda
1.
Open-label, Phase I Study of Nivolumab Combined with nab-Paclitaxel Plus Gemcitabine in Advanced Pancreatic Cancer.
Clin Cancer Res
; 26(18): 4814-4822, 2020 09 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-32554514
2.
Safety and Efficacy Results of a Phase I, Open-Label Study of Concurrent and Delayed Nivolumab in Combination With nab-Paclitaxel and Carboplatin in Advanced Non-small Cell Lung Cancer.
Front Oncol
; 9: 1256, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31850192
3.
A Phase I/II Open-Label Multicenter Single-Arm Study of FABLOx (Metronomic 5-Fluorouracil Plus nab-Paclitaxel, Bevacizumab, Leucovorin, and Oxaliplatin) in Patients with Metastatic Pancreatic Cancer.
J Pancreat Cancer
; 5(1): 35-42, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31559379
4.
Efficacy and safety of a fixed-dose combination of mometasone furoate and formoterol fumarate in subjects with moderate to very severe COPD: results from a 52-week Phase III trial.
Int J Chron Obstruct Pulmon Dis
; 7: 43-55, 2012.
Artículo
en Inglés
| MEDLINE | ID: mdl-22334768
5.
Effects of mometasone furoate/formoterol fumarate fixed-dose combination formulation on chronic obstructive pulmonary disease (COPD): results from a 52-week Phase III trial in subjects with moderate-to-very severe COPD.
Int J Chron Obstruct Pulmon Dis
; 7: 57-71, 2012.
Artículo
en Inglés
| MEDLINE | ID: mdl-22334769
Resultados
1 -
5
de 5
1
Próxima >
>>